Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant?
The Bethesda classification system for thyroid fine needle aspirate (FNA) is used to predict the risk of malignancy and to guide the management of thyroid nodules. We postulated that thyroid malignancies characterized as Bethesda III on FNA have more aggressive features than those classified as Beth...
Gespeichert in:
Veröffentlicht in: | Cancers 2020-09, Vol.12 (9), p.2563 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 9 |
container_start_page | 2563 |
container_title | Cancers |
container_volume | 12 |
creator | Turkdogan, Sena Pusztaszeri, Marc Forest, Veronique-Isabelle Hier, Michael P. Payne, Richard J. |
description | The Bethesda classification system for thyroid fine needle aspirate (FNA) is used to predict the risk of malignancy and to guide the management of thyroid nodules. We postulated that thyroid malignancies characterized as Bethesda III on FNA have more aggressive features than those classified as Bethesda IV. A retrospective chart review was performed to identify those who underwent thyroid surgery at a single tertiary hospital setting between 2015 and 2020. Associations between Bethesda category, molecular genetic test results, and histopathologic findings were examined. Out of 628 surgeries that were performed, 199 (54.2%) Bethesda III nodules and 216 (82.8%) Bethesda IV nodules were malignant. Of those that were malignant, 37 (18.6%) and 22 (10.2%) Bethesda III and Bethesda IV nodules showed aggressive features, respectively (p value = 0.014). There was a proportionally increased number of aggressive features in extra-thyroidal extension, lymph nodes metastasis, and all aggressive subtypes of papillary thyroid cancer in the Bethesda III category. Although Bethesda IV nodules are much more likely to be malignant (p value = 0.002), our study suggests that Bethesda III nodules that are resected are more likely to have aggressive features than Bethesda IV nodules, with a statistically significant increase in the solid variant of papillary thyroid cancer and lymph node metastasis. |
doi_str_mv | 10.3390/cancers12092563 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7564274</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A638190037</galeid><sourcerecordid>A638190037</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-4f3e5c1d728942c7e39442305e037a357022b87ef514c36c76576d3063a578613</originalsourceid><addsrcrecordid>eNplkc1PFTEUxRsjEYKs3TZx4-ZJ29vpndlongT0JaAb1GVTOnc-yLwW2xkS_nv7gChiN21yf-fc0xzG3kjxHqARx94FTylLJRpVGXjBDpRAtTKm0S-fvPfZUc7XohwAiQZfsX1QjTS1wAO2XSfin2geKLeObzYbfjncpTi2_Gtsl4kyv4iFWPd9opzHW-Lz4MITxY__BD8HCvwsLqHlcywkv3DT2AcX5o-v2V7npkxHj_ch-352ennyZXX-7fPmZH2-8lqZeaU7oMrLFlXdaOWRoNFagahIADqoUCh1VSN1ldQejEdToWlBGHAV1kbCIfvw4HuzXG2p9RTm5CZ7k8atS3c2utH-OwnjYPt4a7EyWqEuBu8eDVL8tVCe7XbMnqbJBYpLtqrkURIQoaBvn6HXcUmhfO-e2uVu9F-qdxPZMXSx7PU7U7s2UMumtIOFOn6gfIo5J-r-RJbC7jq3zzqH37Adm6g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2442423094</pqid></control><display><type>article</type><title>Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant?</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Turkdogan, Sena ; Pusztaszeri, Marc ; Forest, Veronique-Isabelle ; Hier, Michael P. ; Payne, Richard J.</creator><creatorcontrib>Turkdogan, Sena ; Pusztaszeri, Marc ; Forest, Veronique-Isabelle ; Hier, Michael P. ; Payne, Richard J.</creatorcontrib><description>The Bethesda classification system for thyroid fine needle aspirate (FNA) is used to predict the risk of malignancy and to guide the management of thyroid nodules. We postulated that thyroid malignancies characterized as Bethesda III on FNA have more aggressive features than those classified as Bethesda IV. A retrospective chart review was performed to identify those who underwent thyroid surgery at a single tertiary hospital setting between 2015 and 2020. Associations between Bethesda category, molecular genetic test results, and histopathologic findings were examined. Out of 628 surgeries that were performed, 199 (54.2%) Bethesda III nodules and 216 (82.8%) Bethesda IV nodules were malignant. Of those that were malignant, 37 (18.6%) and 22 (10.2%) Bethesda III and Bethesda IV nodules showed aggressive features, respectively (p value = 0.014). There was a proportionally increased number of aggressive features in extra-thyroidal extension, lymph nodes metastasis, and all aggressive subtypes of papillary thyroid cancer in the Bethesda III category. Although Bethesda IV nodules are much more likely to be malignant (p value = 0.002), our study suggests that Bethesda III nodules that are resected are more likely to have aggressive features than Bethesda IV nodules, with a statistically significant increase in the solid variant of papillary thyroid cancer and lymph node metastasis.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers12092563</identifier><identifier>PMID: 32916807</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Genetic screening ; Lymph nodes ; Lymphatic system ; Malignancy ; Metastases ; Nodules ; Papillary thyroid cancer ; Pathology ; Patients ; Physiological aspects ; Statistical analysis ; Surgery ; Thyroid cancer ; Tumors</subject><ispartof>Cancers, 2020-09, Vol.12 (9), p.2563</ispartof><rights>COPYRIGHT 2020 MDPI AG</rights><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c426t-4f3e5c1d728942c7e39442305e037a357022b87ef514c36c76576d3063a578613</citedby><cites>FETCH-LOGICAL-c426t-4f3e5c1d728942c7e39442305e037a357022b87ef514c36c76576d3063a578613</cites><orcidid>0000-0001-6490-4189</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564274/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564274/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Turkdogan, Sena</creatorcontrib><creatorcontrib>Pusztaszeri, Marc</creatorcontrib><creatorcontrib>Forest, Veronique-Isabelle</creatorcontrib><creatorcontrib>Hier, Michael P.</creatorcontrib><creatorcontrib>Payne, Richard J.</creatorcontrib><title>Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant?</title><title>Cancers</title><description>The Bethesda classification system for thyroid fine needle aspirate (FNA) is used to predict the risk of malignancy and to guide the management of thyroid nodules. We postulated that thyroid malignancies characterized as Bethesda III on FNA have more aggressive features than those classified as Bethesda IV. A retrospective chart review was performed to identify those who underwent thyroid surgery at a single tertiary hospital setting between 2015 and 2020. Associations between Bethesda category, molecular genetic test results, and histopathologic findings were examined. Out of 628 surgeries that were performed, 199 (54.2%) Bethesda III nodules and 216 (82.8%) Bethesda IV nodules were malignant. Of those that were malignant, 37 (18.6%) and 22 (10.2%) Bethesda III and Bethesda IV nodules showed aggressive features, respectively (p value = 0.014). There was a proportionally increased number of aggressive features in extra-thyroidal extension, lymph nodes metastasis, and all aggressive subtypes of papillary thyroid cancer in the Bethesda III category. Although Bethesda IV nodules are much more likely to be malignant (p value = 0.002), our study suggests that Bethesda III nodules that are resected are more likely to have aggressive features than Bethesda IV nodules, with a statistically significant increase in the solid variant of papillary thyroid cancer and lymph node metastasis.</description><subject>Genetic screening</subject><subject>Lymph nodes</subject><subject>Lymphatic system</subject><subject>Malignancy</subject><subject>Metastases</subject><subject>Nodules</subject><subject>Papillary thyroid cancer</subject><subject>Pathology</subject><subject>Patients</subject><subject>Physiological aspects</subject><subject>Statistical analysis</subject><subject>Surgery</subject><subject>Thyroid cancer</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNplkc1PFTEUxRsjEYKs3TZx4-ZJ29vpndlongT0JaAb1GVTOnc-yLwW2xkS_nv7gChiN21yf-fc0xzG3kjxHqARx94FTylLJRpVGXjBDpRAtTKm0S-fvPfZUc7XohwAiQZfsX1QjTS1wAO2XSfin2geKLeObzYbfjncpTi2_Gtsl4kyv4iFWPd9opzHW-Lz4MITxY__BD8HCvwsLqHlcywkv3DT2AcX5o-v2V7npkxHj_ch-352ennyZXX-7fPmZH2-8lqZeaU7oMrLFlXdaOWRoNFagahIADqoUCh1VSN1ldQejEdToWlBGHAV1kbCIfvw4HuzXG2p9RTm5CZ7k8atS3c2utH-OwnjYPt4a7EyWqEuBu8eDVL8tVCe7XbMnqbJBYpLtqrkURIQoaBvn6HXcUmhfO-e2uVu9F-qdxPZMXSx7PU7U7s2UMumtIOFOn6gfIo5J-r-RJbC7jq3zzqH37Adm6g</recordid><startdate>20200909</startdate><enddate>20200909</enddate><creator>Turkdogan, Sena</creator><creator>Pusztaszeri, Marc</creator><creator>Forest, Veronique-Isabelle</creator><creator>Hier, Michael P.</creator><creator>Payne, Richard J.</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6490-4189</orcidid></search><sort><creationdate>20200909</creationdate><title>Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant?</title><author>Turkdogan, Sena ; Pusztaszeri, Marc ; Forest, Veronique-Isabelle ; Hier, Michael P. ; Payne, Richard J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-4f3e5c1d728942c7e39442305e037a357022b87ef514c36c76576d3063a578613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Genetic screening</topic><topic>Lymph nodes</topic><topic>Lymphatic system</topic><topic>Malignancy</topic><topic>Metastases</topic><topic>Nodules</topic><topic>Papillary thyroid cancer</topic><topic>Pathology</topic><topic>Patients</topic><topic>Physiological aspects</topic><topic>Statistical analysis</topic><topic>Surgery</topic><topic>Thyroid cancer</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Turkdogan, Sena</creatorcontrib><creatorcontrib>Pusztaszeri, Marc</creatorcontrib><creatorcontrib>Forest, Veronique-Isabelle</creatorcontrib><creatorcontrib>Hier, Michael P.</creatorcontrib><creatorcontrib>Payne, Richard J.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Turkdogan, Sena</au><au>Pusztaszeri, Marc</au><au>Forest, Veronique-Isabelle</au><au>Hier, Michael P.</au><au>Payne, Richard J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant?</atitle><jtitle>Cancers</jtitle><date>2020-09-09</date><risdate>2020</risdate><volume>12</volume><issue>9</issue><spage>2563</spage><pages>2563-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>The Bethesda classification system for thyroid fine needle aspirate (FNA) is used to predict the risk of malignancy and to guide the management of thyroid nodules. We postulated that thyroid malignancies characterized as Bethesda III on FNA have more aggressive features than those classified as Bethesda IV. A retrospective chart review was performed to identify those who underwent thyroid surgery at a single tertiary hospital setting between 2015 and 2020. Associations between Bethesda category, molecular genetic test results, and histopathologic findings were examined. Out of 628 surgeries that were performed, 199 (54.2%) Bethesda III nodules and 216 (82.8%) Bethesda IV nodules were malignant. Of those that were malignant, 37 (18.6%) and 22 (10.2%) Bethesda III and Bethesda IV nodules showed aggressive features, respectively (p value = 0.014). There was a proportionally increased number of aggressive features in extra-thyroidal extension, lymph nodes metastasis, and all aggressive subtypes of papillary thyroid cancer in the Bethesda III category. Although Bethesda IV nodules are much more likely to be malignant (p value = 0.002), our study suggests that Bethesda III nodules that are resected are more likely to have aggressive features than Bethesda IV nodules, with a statistically significant increase in the solid variant of papillary thyroid cancer and lymph node metastasis.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>32916807</pmid><doi>10.3390/cancers12092563</doi><orcidid>https://orcid.org/0000-0001-6490-4189</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2072-6694 |
ispartof | Cancers, 2020-09, Vol.12 (9), p.2563 |
issn | 2072-6694 2072-6694 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7564274 |
source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Genetic screening Lymph nodes Lymphatic system Malignancy Metastases Nodules Papillary thyroid cancer Pathology Patients Physiological aspects Statistical analysis Surgery Thyroid cancer Tumors |
title | Are Bethesda III Thyroid Nodules More Aggressive than Bethesda IV Thyroid Nodules When Found to Be Malignant? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T12%3A25%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Are%20Bethesda%20III%20Thyroid%20Nodules%20More%20Aggressive%20than%20Bethesda%20IV%20Thyroid%20Nodules%20When%20Found%20to%20Be%20Malignant?&rft.jtitle=Cancers&rft.au=Turkdogan,%20Sena&rft.date=2020-09-09&rft.volume=12&rft.issue=9&rft.spage=2563&rft.pages=2563-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers12092563&rft_dat=%3Cgale_pubme%3EA638190037%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2442423094&rft_id=info:pmid/32916807&rft_galeid=A638190037&rfr_iscdi=true |